Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: Comparison with an aldose reductase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 1, 1996, Pages 49-55

  Hotta, Nigishi ^a   Koh, Naoki ^a   Sakakibara, Fumihiko ^a   Nakamura, Jiro ^a   Hamada, Yoji ^a   Wakao, Takaaki ^a   Hara, Tomohiro ^a   Mori, Koichi ^a   Naruse, Keiko ^a   Nakashima, Eitaro ^a   Sakamoto, Nobuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[5 (3 THIENYL)TETRAZOL 1 YL]ACETIC ACID; ALDOSE REDUCTASE INHIBITOR; CARNITINE DERIVATIVE; CHOLESTEROL; GLUCOSE; PROPIONYLCARNITINE; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HEART AUTOMATICITY; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARBOHYDRATE METABOLISM; CARDIOTONIC AGENTS; CARNITINE; CAUDA EQUINA; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; HEART CONDUCTION SYSTEM; LIPIDS; MALE; MOTOR NEURONS; NEURAL CONDUCTION; RATS; RATS, WISTAR; SCIATIC NERVE; TETRAZOLES; THIOPHENES;

EID: 0029670419     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. ANGELUCCI, L., RAMACCI, M. T., TAGLIALATELA, G., HULSEBOSCH, C., MORGAN, B., WERRBACH, P. K. AND PEREZ, P. R.: Nerve growth factor binding in aged rat central nervous system: Effect of acetyl-L-carnitine. J. Neurosci. Res. 20: 491-496, 1988.
2. APFEL, S. C., AREZZO, J. C., BROWNLEE, M., FEDERHOFF, H. AND KESSLER, J. A.: Nerve growth factor treatment ameliorates diabetic sensory neuropathy. Diabetes 41: suppl 1, 140A, 1992.
3. ARDUINI, A., GORBUNOV, N., ARRIGONI-MARTELLI, E., DOTTORI, S., MOLAJONI, F., RUSSO, F. AND FEDERICI, G.: Effect of L-carnitine and its acetate and propionate esters on the molecular dynamics of human erythrocyte membrane. Biochem. Biophys. Acta 1146: 229-235, 1993.
4. BERTELLI, A., BERTELLI, A. A., GALMOZZI, G., GIOVANNINI, L. AND MIAN, M.: Thrombosis induced by endothelin (ET-1) and carrangeenin in rats treated with idomethacin and propionyl carnitine. Drugs Exp. Clin. Res. 19: 75-78, 1993.
5. BREMER, J.: Carnitine-metabolism and functions. Physiol. Rev. 63: 1420-1480, 1983.
6. CAMERON, N. E., COTTER, M. A. AND LOW, P. A.: Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am. J. Physiol. 261: E 1-8, 1991.
7. CAMERON, N. E. AND COTTER, M. A.: Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies. Diabetic Med. 10: 593-605, 1993.
8. CORR, P. B., GROSS, R. W. AND SOBEL, B. E.: Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ. Res. 55: 135-154, 1984.
9. DUNLAP, E. D., SAMOLS, E., WAITE, L. C. AND PFEIFER, M. A.: Development of a method to determine autonomic nervous system function in the rat. Metabolism 36: 193-197, 1987.
10. DYCK, P. J.: Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy? Neurology 39: 111-118, 1989.
11. FERRARI, R., CECONI, C., CURELLO, S., PASINI, E. AND VISIOLI, O.: Protective effect of propionyl-L-carnitine against ischemia and reperfusion damage. Mol. Cell Biochem. 88: 161-168, 1989.
12. GARRELDS, I. M., ELLIOTT, G. E., ZIJLSTRA, F. J. AND BONTA, I. L.: Effects of short- and long-term feeding of L-carnitine and congeners on the production of eicosanoids from rat peritoneal leukocytes. Br. J. Nutr. 72: 785-793, 1994.
13. GORIO, A , DIGUILO, A. M., TENCONI, B., DONADONI, L., GERMANI, E., BERTELLI, A., MANTEGAZZA, P., MACCARI, P. AND RAMACCI, M. T.: Peptide alterations in autonomic diabetic neuropathy prevented by acetyl-L-carnitine. Int. J. Clin. Pharm. Res. 12: 225-230, 1992.
14. GREENE, D. A., LATTIMER-GREENE, S. A. AND SIMA, A. A. F.: Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab. Rev. 4: 201-212, 1988.
15. HAMSTEN, A., WIMAN, B., FAIRE, U. AND BLOMBÄCK, M.: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Eng. J. Med. 313: 1557-1563, 1985.
16. HANAOKA, Y., OHI, T., FURUKAWA, S., FURUKAWA, Y., HAYASHI, K. AND MATSUOKA, S.: Effect of 4-methyl-catechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats. Exp. Neurol. 115: 292-296, 1992.
17. HOTTA, N., KAKUTA, H., FUKASAWA, H., KIMURA, M., KOH, N., IIDA, M., TERASHIMA, H., MORIMURA, T. AND SAKAMOTO, N.: Effects of a fuctose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia 28: 176-180, 1985.
18. HOTTA, N., KAKUTA, H., FUKASAWA, H., KOH, N., SAKAKIBARA, F., KOMORI, H. AND SAKAMOTO, N.. Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 41: 587-591, 1992.
19. HOTTA, N., KAKUTA, H., FUKASAWA, H., KOH, N., SAKAKIBARA, F., NAKAMURA, J., HAMADA, Y., WAKAO, T., HARA, T., MORI, K., NARUSE, K., NAKASHIMA, E., INUKAI, S. AND SAKAMOTO, N.: Effect of a potent aldose reductase inhibitor, (5-(3-thienyl)tetrazol-1-yl) acetic acid (TAT), on diabetic neuropathy in rats. Diabetes Res. Clin. Prac., 27: 107-117, 1995.
20. HOTTA, N. AND SAKAMOTO, N.: Aldose reductase inhibitors. In The Diabetes Annual 5, ed. by K. G. G. M. Alberti and L. P. Krall, pp. 330-361, Elsevier Science Publishers B.V., Amsterdam, 1990.
21. HULSMAN, W. C.: Biochemical profile of propionyl-L-carnitine. Cardiovasc. Drugs Ther. 5: 7-10, 1991.
22. IDO, Y., MCHOWAT, J., CHANG, K. C., ARRIGONI-MARTELLI, E., ORFALIAN, Z., KILO, C., CORR, P. B. AND WILLIAMSON, J. R.: Neural dysfunction and metabolic imbalances in diabetic rat. Prevention by acetyl-L-carnitine. Diabetes 43: 1469-1477, 1994.
23. INUKAI, S., AGATA, M., SATO, M., NAITO, A., MATSUKAWA, H. AND GOTO, M.: Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy. Jpn. J. Pharmacol. 61: 221-227, 1993.
24. JAMAL, G. A.: Pathogenesis of diabetic neuropathy: The role of the n-6 essential fatty acids and their eicosanoid derivatives. Diabetic Med. 7: 574-579, 1990.
25. KOSHU, K., KAMIYAMA, K, OKA, N., ENDO, S., TAKAKU, A. AND SAITO, T.: Measurement of regional blood flow using hydrogen gas generated by electrolysis. Stroke 13: 483-487, 1982.
26. KOTAKA, Z., MIYAZAKI, Y., OGAWA, K., SATAKE, T., KITAZAWA, M., SUGIYAMA, O. AND OZAWA, T.: Protective effects of carnitine and its derivatives against free fatty acid-induced mitochondrial dysfunction. J. Appl. Biochem. 3: 328-336, 1981.
27. LOWITT, S., CARVER, J., MIRANDA, C. AND MALONE, J.: Acetyl-L-carnitine (ALC) effect upon derangements in fatty acid metabolism and structural abnormalities in experimental diabetic neuropathy. Diabetes 42: suppl 1, 17A, 1993.
28. LOW, P. A., SCHMELZER, J. D., WARD, K. K AND YAO, J. K.: Experimental chronic hypoxic neuropathy: Relevance to diabetic neuropathy. Am. J. Physiol. 250: E 94-96, 1986.
29. LOW, P. A., LAGERLUND, T. D. AND MCMANIS, P. G.: Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int. Rev. Neurobiol. 31: 355-438, 1989.
30. MALONE, J. I., LOWITT, S., CORSICO, N. AND ORFALIAN, Z.: Altered neuroexcitability in experimental diabetic neuropathy: Effect of acetyl-L-carnitine. Int. J. Clin. Pharm. Res. 12: 237-241, 1992.
31. MAYES, P. A.: Gluconeogenesis and control of the blood glucose. In Harper's Biochemistry, ed. by R. K. Murray, D. K. Granner, P. A. Mayes and V. W. Rodwell, pp. 190-200, Appleton & Lange, East Norwalt, CT, 1993.
32. MCGARRY, J. D. AND FOSTER, D. W.: An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J. Lipid Res. 17: 277-281, 1976.
33. MIYOSHI, T. AND GOTO, I.: Serial in vivo determinations of nerve conduction velocity in rat tails: Physiological and pathological changes. Electroencephalogr Clin. Neurophysiol. 35: 125-131, 1973.
34. MIZUNO, K., KATO, N., MATSUBARA, A., NAKANO, K. AND KURONO, M.: Effects of a new aldose reductase inhibitor, (2S, 4S:)-6-fluoro2′, 5′-dioxospiro [chroman4,4-imidazolidinine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41: 1081-1086, 1992.
35. NAKADATE, T. AND BLUMBERG, P. M.: Modulation by palmitoylcarnitine of PKC activation. Cancer Res. 47: 6537-6542, 1987.
36. NISHIZUKA, Y.: Intracellular signaling by hydrolysis of phospholipids and activation of PKC. Science 258: 607-614, 1992.
37. PACIFICI, L., BELLUCCI, A., PIOVESAN, P., MACCARI, F., GORIO, A. AND MACCARI, M. T.: Counteraction on experimentally induced diabetic neuropathy by levocarnitine acetyl. Int. J Clin. Pharm. Res. 12: 231-236, 1992.
38. PASINI, E., COMINI, L., FERRARI, R., DEGIULI, F., MENOTTI, A. AND DHALLA, N. S.: Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Am. J. Cardiovasc. Pathol. 4: 216-222, 1992.
39. PAULSON, D. J , SCHMIDT, M. J., TRAXLER, J. S., PAMACCI, M. T. AND SHUG, A. L.: Improvement of myocardial function in diabetic rats after treatment with L-carnitine. Metabolism 33: 358-363, 1984a.
40. PAULSON, D. J., SCHMIDT, M. J., ROMENS, J. AND SHUG, A. L.: Metabolic and physiological differences between zero-flow and low-flow myocardial ischemia: Effects of L-acetylcarnitine. Basic. Res. Cardiol 79: 551-561, 1984b.
41. PAULSON, D. J., TRAXLER, J., SCHMIDT, M., NOOAN, J. AND SHUG, A. L.: Protection of the ischaemic myocardium by L-propionylcarnitine: Effects on the recovery of cardiac output after ischemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc. Res. 20: 536-541, 1986.
42. PEIPER, G. M. AND MURRAY, W. J.: In vivo and in vitro intervention with L-carnitine prevents abnormal energy metabolism in isolated diabetic rat heart: Chemical and phosphorous-31 NMR evidence. Biochem. Med. Metab. Biol. 38: 111-120, 1987.
43. POLA, P., DEMARTINI, D., GERARDINO, L., DEROSSI, S. AND TONDI, P.: The action of propionyl-L-carnitine on the vasal endothelium: Increased t-PA synthesis and a decrease in the activity of PA-1. A preliminary study. Drugs Exp. Clin. Res. 18: 343-348, 1992.
44. RODRIGUES, B., XIANG, H. AND MCNEIL, J. H.: Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37: 1358-1364, 1988.
45. TAGLIALATELA, G., ANGELACCI, L., RAMACCI, M. T., WERRBACH, P. K., JACKSON, G. R. AND PEREZ, P. JR.: Acetyl-L-carnitine enhances the response of PC 12 cells to nerve growth factor. Dev. Brain. Res. 59: 221-230, 1991.
46. TESCO, G., LATORRACO, S., PIERSANTI, P., PLACENTINI, S., AMADUCCI, L. AND SORBI, S.: Protection from oxygen radical damage in human diploid fibroblasts by acetyl-L-carnitine. Dementia 3: 58-60, 1992.
47. TESFAYE, S., MALIK, R. AND WARD, J. D.: Vascular factors in diabetic neuropathy. Diabetologia 37: 847-854, 1994.
48. TILTON, R. G., CHANG, K., PUGLIESE, G., EADES, D. M., PROVINCE, M. A., SHERMAN, W. R., KILO, C. AND WILLIAMSON, J. R.: Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors Diabetes 38: 1258-1270, 1989.
49. VAN-HINSBERGH, V. W. ANB SCHEFFER, M. A : Effect of propionyl-L-carnitine on human endothelial cells. Cardiovasc. Drugs. Ther. 5: suppl 1, 95-105, 1991.
50. VARY, T C AND NEELY, J. R.: A mechanism for reduced myocardial carnitine levels in diabetic animals. Am. J. Physiol. 243: H 154-158, 1982.
51. VINIK, A. I., HOLLAND, M. T., LE BEAU, J. M., LIUZZI, F. J., STANSBERRY, K. B. AND COLEN, L. B.. Diabetic neuropathies Diabetes Care 15: 1926-1975, 1992.
52. WILLIAMSON, J. R., CHANG, K., FRANGOS, M., HASAN, K. S., IDO, Y., KAWAMURA, T., NYENGAARD, J. R., ENDEN, M. V. D., KILO, C. AND TILTON, R. G.: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
53. YAMADA, H., HOTTA, N., NAKAMURA, J., KOH, N., SAKAKIBARA, F., KOMORI, T., HAMADA, Y., WAKAO, T., HARA, T., MORI, K., NARUSE, K., NAKASHIMA, E., KAKUTA, H., FUKASAWA, H., MIZUNO, K., MATSUBARA, A. AND SAKAMOTO, N.: The preventive effect of an aldose reductase inhibitor, SNK-860, on diabetic somatic and autonomic neuropathy in streptozotocin-induced diabetic rats. J. Jpn. Diab. Soc. 36: 693-700, 1993.
54. 1 analogue TFC 612 on diabetic neuropathy in streptozotocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO-2235. Diabetes 38: 832-836, 1989.